title: Phase I dose-escalation trial of irinotecan with continuous infusion 5-FU first line, in metastatic colorectal cancer.
authors.affiliation: Department of Clinical Oncology, Christie Hospital, Wilmslow Road, Manchester, M20 4BX, UK. mark.saunders@christie-tr.nwest.nhs.uk
authors.forename: M P
authors.initials: MP
authors.lastname: Saunders
authors.forename: M
authors.initials: M
authors.lastname: Hogg
authors.forename: B
authors.initials: B
authors.lastname: Carrington
authors.forename: A-M
authors.initials: AM
authors.lastname: Sjursen
authors.forename: J
authors.initials: J
authors.lastname: Allen
authors.forename: J
authors.initials: J
authors.lastname: Beech
authors.forename: R
authors.initials: R
authors.lastname: Swindell
authors.forename: J W
authors.initials: JW
authors.lastname: Valle
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D000077146:Irinotecan; D002955:Leucovorin / Q000008:administration & dosage; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008207:Lymphatic Metastasis / Q000473:pathology*; D008297:Male; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D000077146:Irinotecan; D002955:Leucovorin; D002166:Camptothecin